Hixita-M 50 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, thereby increasing insulin release and decreasing glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. The synergistic action of these agents helps achieve better glycemic control by targeting multiple pathophysiological defects associated with type 2 diabetes. Hixita-M 50 is prescribed as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on either component alone or when dual therapy is appropriate. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerability. Hixita-M 50 should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.